TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
scientific article published on 16 January 2017
Author/s
author: Delphine Maucort-Boulch, Meyling H Cheok, Didier Auboeuf, Charles Dumontet, Olivier Nibourel, Claude Preudhomme, Franck Mortreux, Sandrine Hayette, Mauricette Michallet, Nicolas Boissel, Isabelle Tigaud, Aminetou Mint Mohamed, Marie Balsat, Catherine Koering, Pascale Flandrin-Gresta, Franck E Nicolini, Françoise Solly, Denis Guyotat, Lydia Campos, Eric Wattel
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.